BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Witt S, Krauss E, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells AU, Vasakova M, Pesci A, Klepetko W, Seeger W, Crestani B, Leidl R, Holle R, Schwarzkopf L, Guenther A. Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respir Res 2019;20:47. [PMID: 30823880 DOI: 10.1186/s12931-019-1010-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Loeh B, Brylski LT, von der Beck D, Seeger W, Krauss E, Bonniaud P, Crestani B, Vancheri C, Wells AU, Markart P, Breithecker A, Guenther A. Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality. Chest 2019;155:972-81. [DOI: 10.1016/j.chest.2019.01.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
2 Krauss E, Froehler M, Degen M, Mahavadi P, Dartsch RC, Korfei M, Ruppert C, Seeger W, Guenther A. Exhalative Breath Markers Do Not Offer for Diagnosis of Interstitial Lung Diseases: Data from the European IPF Registry (eurIPFreg) and Biobank. J Clin Med 2019;8:E643. [PMID: 31075945 DOI: 10.3390/jcm8050643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Krauss E, Gehrken G, Drakopanagiotakis F, Tello S, Dartsch RC, Maurer O, Windhorst A, von der Beck D, Griese M, Seeger W, Guenther A. Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF). BMC Pulm Med 2019;19:130. [PMID: 31319833 DOI: 10.1186/s12890-019-0895-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
4 Kang M, Veeraraghavan S, Martin GS, Kempker JA. An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis. ERJ Open Res 2021;7:00142-2021. [PMID: 34671666 DOI: 10.1183/23120541.00142-2021] [Reference Citation Analysis]
5 Whittal A, Meregaglia M, Nicod E. The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment. Patient 2021;14:485-503. [PMID: 33462774 DOI: 10.1007/s40271-020-00493-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry investigators. Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry. Respir Med 2021;189:106637. [PMID: 34656903 DOI: 10.1016/j.rmed.2021.106637] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 O’brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB, Asi W, Baker A, Beegle S, Belperio JA, Condos R, Cordova F, Culver DA, de Andrade JA, Dilling D, Flaherty KR, Glassberg M, Gulati M, Guntupalli K, Gupta N, Hajari Case A, Hotchkin D, Huie T, Kaner R, Kim H, Kreider M, Lancaster L, Lasky J, Lederer D, Lee D, Liesching T, Lipchik R, Lobo J, Mageto Y, Menon P, Morrison L, Namen A, Oldham J, Raj R, Ramaswamy M, Russell T, Sachs P, Safdar Z, Sigal B, Silhan L, Strek M, Suliman S, Tabak J, Walia R, Whelan TP. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. Chest 2020;157:1188-98. [DOI: 10.1016/j.chest.2019.11.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
8 Shaikh SB, Najar MA, Prabhu A, Rex DAB, Chanderasekaran J, Behera SK, Modi PK, Prasad TSK, Bhandary YP. The unique molecular targets associated antioxidant and antifibrotic activity of curcumin in in vitro model of acute lung injury: A proteomic approach. Biofactors 2021;47:627-44. [PMID: 33864298 DOI: 10.1002/biof.1732] [Reference Citation Analysis]
9 Krauss E, El-Guelai M, Pons-Kuehnemann J, Dartsch RC, Tello S, Korfei M, Mahavadi P, Breithecker A, Fink L, Stoehr M, Majeed RW, Seeger W, Crestani B, Guenther A. Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg). J Clin Med 2020;9:E2499. [PMID: 32756496 DOI: 10.3390/jcm9082499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Kalluri M, Luppi F, Ferrara G. What Patients With Idiopathic Pulmonary Fibrosis and Caregivers Want: Filling the Gaps With Patient Reported Outcomes and Experience Measures. Am J Med 2020;133:281-9. [PMID: 31520625 DOI: 10.1016/j.amjmed.2019.08.032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
11 Krauss E, Tello S, Wilhelm J, Schmidt J, Stoehr M, Seeger W, Dartsch RC, Crestani B, Guenther A. Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg). J Clin Med 2020;9:E3763. [PMID: 33266405 DOI: 10.3390/jcm9113763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Lu Y, Dai Z, Lu Y, Chang F. Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis. BMJ Open 2022;12:e058497. [PMID: 35414559 DOI: 10.1136/bmjopen-2021-058497] [Reference Citation Analysis]
13 Kirsten D, de Vries U, Costabel U, Koschel D, Bonella F, Günther A, Behr J, Claussen M, Schwarz S, Prasse A, Kreuter M. A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia. Pneumologie 2021. [PMID: 34521147 DOI: 10.1055/a-1579-7618] [Reference Citation Analysis]
14 Cox IA, Borchers Arriagada N, de Graaff B, Corte TJ, Glaspole I, Lartey S, Walters EH, Palmer AJ. Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur Respir Rev 2020;29:200154. [PMID: 33153990 DOI: 10.1183/16000617.0154-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Antoniou K, Kamekis A, Symvoulakis EK, Kokosi M, Swigris JJ. Burden of idiopathic pulmonary fibrosis on patients’ emotional well being and quality of life: a literature review. Current Opinion in Pulmonary Medicine 2020;26:457-63. [DOI: 10.1097/mcp.0000000000000703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Vanem TT, Rand-Hendriksen S, Brunborg C, Geiran OR, Røe C. Health-related quality of life in Marfan syndrome: a 10-year follow-up. Health Qual Life Outcomes 2020;18:376. [PMID: 33256748 DOI: 10.1186/s12955-020-01633-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Luckett T, San Martin A, Currow DC, Johnson MJ, Barnes-harris MM, Phillips JL. A systematic review and meta-analysis of studies comparing burden from lung cancer and chronic obstructive pulmonary disease. Palliat Med 2020;34:1291-304. [DOI: 10.1177/0269216320940153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Auld JP, Thompson EA, Dougherty CM. Profiles of partner health linked to a partner-focused intervention following patient initial implantable cardioverter defibrillator (ICD). J Behav Med 2021. [PMID: 33974172 DOI: 10.1007/s10865-021-00223-z] [Reference Citation Analysis]
19 Aguiar WF, Mantoani LC, Silva H, Zamboti CL, Garcia T, Cavalheri V, Ribeiro M, Yorke J, Pitta F, Camillo CA. Translation, cross-cultural adaptation, and measurement properties of the Brazilian-Portuguese version of the idiopathic pulmonary fibrosis-specific version of the Saint George's Respiratory Questionnaire (SGRQ-I) for patients with interstitial lung disease. Braz J Phys Ther 2021:S1413-3555(21)00075-7. [PMID: 34348865 DOI: 10.1016/j.bjpt.2021.06.008] [Reference Citation Analysis]
20 Kalluri M, Luppi F, Vancheri A, Vancheri C, Balestro E, Varone F, Mogulkoc N, Cacopardo G, Bargagli E, Renzoni E, Torrisi S, Calvello M, Libra A, Pavone M, Bonella F, Cottin V, Valenzuela C, Wijsenbeek M, Bendstrup E; 3rd International Summit for ILD (ISILD), Erice collaborators listed below. Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here? Eur Respir Rev 2021;30:210026. [PMID: 34039675 DOI: 10.1183/16000617.0026-2021] [Reference Citation Analysis]
21 de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res 2022;23:3. [PMID: 34996465 DOI: 10.1186/s12931-021-01921-7] [Reference Citation Analysis]
22 Yuan XY, Zhang H, Huang LR, Zhang F, Sheng XW, Cui A. Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases. PLoS One 2020;15:e0236346. [PMID: 32726327 DOI: 10.1371/journal.pone.0236346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S, Calvert MJ, Deeks JJ, Steeds RP, Strauss VY, Rahimi K, Camm AJ, Griffith M, Lip GYH, Townend JN, Kirchhof P; Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA 2020;324:2497-508. [PMID: 33351042 DOI: 10.1001/jama.2020.23138] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 25.5] [Reference Citation Analysis]
24 van der Meulen M, Verstegen MJT, Lobatto DJ, Kleijwegt MC, Pereira AM, Biermasz NR, van Furth WR, Zamanipoor Najafabadi AH. Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study. Pituitary 2022. [PMID: 35001298 DOI: 10.1007/s11102-021-01199-4] [Reference Citation Analysis]
25 Kang M, Marts L, Kempker JA, Veeraraghavan S. Minimal clinically important difference in idiopathic pulmonary fibrosis. Breathe (Sheff) 2021;17:200345. [PMID: 34295421 DOI: 10.1183/20734735.0345-2020] [Reference Citation Analysis]